Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13915 – 13928
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6521

COVID-19: An Interdisciplinary Approach to Emergency Care, Laboratory Diagnostics, Pharmaceutical Management, Social Services, and Industrial Security

Faisal Mohammed N Bin Sanad[1], Ahmad Naif Helal Alotaibi[2], Ali Abdu Hassan[3], Nawaf Hulayyil Suwayjan Alsharari[4], Adel Gassem Mohammad Alameer[5], Mazen Saeed Alturqi Alsharari[6], Abdulellah Mokhlaf Alali[7], Mohammed Shaker Mousa Faqihi[8], Nada Saleh Almaklhafi[9], Hayel Salem Alonazi[10], Alanoud Nasser Alsubaie[11], Hatim Yahya A Daghriri[12], Masfer Fahad Al Dawseri[13], Ibrahim Manzil Hadban Alsharari[14], Talal Shoei Hamad Qumayri[15]

Abstract

The COVID-19 pandemic, caused by SARS-CoV-2, has posed unprecedented global challenges, with over 601 million confirmed cases and 6.4 million deaths reported by September 2022. The virus's rapid mutation rate, emergence of variants of concern (VOCs), and socio-economic disparities have complicated its management. Concurrent outbreaks of other infectious diseases, environmental factors, and healthcare inequities have further exacerbated the crisis. Effective management requires an interdisciplinary approach, integrating emergency care, laboratory diagnostics, pharmaceutical interventions, social services, and industrial security.This article aims to provide a comprehensive overview of the interdisciplinary strategies employed to combat COVID-19, focusing on emergency care, diagnostic advancements, pharmaceutical management, vaccination, and the roles of social services and industrial security in mitigating the pandemic's impact.The study synthesizes data from global health organizations, clinical trials, and research studies. It examines diagnostic tools such as RT-PCR, RT-LAMP, and CRISPR-Cas12, therapeutic interventions like monoclonal antibodies and antiviral drugs, and vaccination strategies. The roles of social services in healthcare access, financial aid, and mental health support, alongside industrial security measures in workplace safety and supply chain management, are also analyzed.Diagnostic advancements have improved COVID-19 detection, with RT-PCR remaining the gold standard. Therapeutic interventions, including monoclonal antibodies and antiviral drugs like molnupiravir, have shown efficacy in reducing mortality and hospitalization rates. Vaccination campaigns have achieved significant global coverage, with mRNA vaccines demonstrating high efficacy against multiple variants. Social services and industrial security have played critical roles in supporting vulnerable populations, ensuring workplace safety, and maintaining supply chain integrity.The COVID-19 pandemic underscores the importance of interdisciplinary collaboration in managing global health crises. Continued advancements in diagnostics, therapeutics, and vaccination, coupled with robust social services and industrial security measures, are essential for mitigating the pandemic's impact and preparing for future health emergencies.

Keywords: *COVID-19, SARS-Cov-2, Diagnostics, Therapeutics, Vaccination, Social Services, Industrial Security, Interdisciplinary Approach.*

[1] Ksa, Ministry of Health, Thadig General Hospital
[2] Ksa, Ministry of Health, Al-Bajadia Hospital.
[3] Ksa, Ministry of Health, Mahayil General Hospital.
[4] Ksa, Ministry of Health, Al-Jouf Health Pool.
[5] Ksa, Ministry of Health, Adiriyah Hospital
[6] Ksa, Ministry of Health, Al-Jouf Health Pool
[7] Ksa, Ministry of Health, Thadiq General Hospital
[8] Ksa, Ministry of Health, Bani Malek General Hospital
[9] Ksa, Ministry of Health, King Abdulaziz Medical City -Riyadh
[10] Ksa, Ministry of Health, King Abdulaziz Medical City -Riyadh
[11] Ksa, Ministry of Health, King Abdulaziz Medical City -Riyadh
[12] Ksa, Ministry of Health, Jazan Regional Laboratory
[13] Ksa, Ministry of Health, Wadi Al- Dawasir Ganeral Hospital
[14] Ksa, Ministry of Health, Al-Jouf Health Pool
[15] Ksa, Ministry of Health, Primary Health Care Center Al-Seeh In Al-Kharj

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13915 – 13928
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6521

Introduction

Viruses are intracellular pathogens that often emerge abruptly and infect large populations within a short timeframe. The first outbreak of severe acute respiratory syndrome coronavirus (SARS-CoV) occurred in 2002, followed by the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, and the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) in December 2019 [1, 2]. According to the World Health Organization (WHO), as of September 2, 2022, over 601 million confirmed COVID-19 cases and 6.4 million deaths have been reported globally, with these numbers continuing to escalate [3]. Several factors complicate the management of COVID-19. Social factors, such as vaccine hesitancy [4], healthcare disparities due to social inequities [5], and inadequate social protection [6], play a significant role. Economic inequalities further exacerbate the situation [5]. Concurrent outbreaks of other infectious diseases, including monkeypox, severe acute hepatitis of unknown origin, multi-organ failure, and black fungus eye infections, have added to the complexity of COVID-19 management [7, 8]. Notably, an outbreak of severe acute hepatitis in children has been reported in the United Kingdom, regions of the Americas, the Western Pacific, Southeast Asia, and the Eastern Mediterranean [9]. Environmental factors, such as pollution, chemical exposures, climate, and the built environment, also contribute to complications in managing COVID-19 [10].

The US government has established the SARS-CoV-2 Interagency Group (SIG), which classifies viral variants into three categories: (1) Variant Being Monitored (VbM), (2) Variant of Interest (VOI), and (3) Variant of Concern (VOC). A fourth category, Variant of High Consequence (VOHC), has also been defined, though no such variant has been identified in the US to date [11]. Currently, the predominant VOCs are various lineages of the Omicron variant [12, 13, 14]. The WHO has adopted a similar classification system for SARS-CoV-2 variants, including VOI, VOC, and VOHC. The SARS-CoV-2 virus comprises five structural proteins, with the spike (S) glycoprotein being the primary protein involved in host cell interaction. The S protein binds to the host cell's angiotensin-converting enzyme 2 (ACE2) receptors, facilitating viral entry [2]. Studies indicate that the most effective therapeutic agents target the interaction between the S protein and ACE2 receptors [15]. However, the Omicron variant exhibits enhanced binding affinity to ACE2 receptors and employs a distinct invasion mechanism, utilizing the endosomal route independent of Transmembrane protease, serine 2 (TMPRSS2) [16]. The BA.1 and BA.2 subvariants of Omicron also favor this TMPRSS2-independent entry pathway, which is associated with specific regions of the spike protein. These changes in antigenicity contribute to the rapid transmission and altered pathogenicity of Omicron variants [17]. Additionally, the modified entry mechanism of Omicron variants enables infection in various animal species, such as horseshoe bats, mice, and domesticated birds, increasing the risk of reverse zoonosis [16]. According to the WHO, Omicron accounted for 99.6% of sequenced cases reported between July 29 and August 29, 2022 [18].

Recent research highlights that the replication complex of SARS-CoV-2 includes the fastest RNA-dependent RNA polymerase among coronaviruses [19]. This rapid elongation mechanism increases the likelihood of mismatch mutations, leading to high genomic variability and the emergence of diverse viral strains with distinct characteristics. This variability complicates the development of effective antiviral drugs [20]. Despite its high transmission rate, SARS-CoV-2 has a relatively low mutation rate of 1×10^{-6} per replication cycle, compared to influenza viruses, which mutate at a rate of 3×10^{-5}. This lower mutation rate is attributed to the virus's linear genome and the presence of a proofreading mechanism (nsp14), which is absent in influenza viruses. Consequently, vaccines against SARS-CoV-2 offer longer-lasting protection than those for influenza [21, 22]. New viral variants arise through two primary mechanisms: random point mutations (e.g., Alpha, Beta, Gamma, Mu, Delta, and Omicron) and recombination (observed in coronaviruses, influenza viruses, and HIV) [14, 23, 24]. In coronaviruses, genetic diversity is driven by mutations, recombination, horizontal gene transfer, and gene duplication. Homologous recombination and gene transfer enhance genomic plasticity, enabling the acquisition and modification of genes [25]. This adaptability allows coronaviruses to infect new hosts by evolving interactions between their spike proteins and host cell receptors, a process driven by natural selection [26]. Variants such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.1.529 (Omicron) are associated with high transmission rates [27]. The

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13915 – 13928
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6521

B.1.617.2 (Delta) variant, responsible for India's second COVID-19 wave [28, 29], became the dominant global variant in 2021 [30]. Different viral strains exhibit varying disease progression patterns [31].

The emergence of novel hybrid strains poses a significant threat, potentially exacerbating the pandemic by increasing infection rates. To date, three recombinant Omicron variants—XD, XE, and XF—have been identified. The XD variant resulted from recombination between Delta and the BA.1 lineage of Omicron, while XF emerged from recombination between BA.1 and the UK Delta variant [23]. The BA.4 and BA.5 Omicron subvariants, which share similarities with BA.2, contain unique spike protein mutations such as L452R and F486V. These variants can infect individuals immune to other Omicron variants, leading to increased hospitalizations [32]. According to the WHO's August 2022 report, the BA.5 lineage accounted for 78.2% of global cases, reflecting its dominance [18]. The emergence of new variants of concern, driven by genomic mutations, poses significant challenges for treatment and vaccination. Many repurposed drugs and vaccines lose efficacy against these variants. For instance, monoclonal antibodies targeting the spike protein, such as VIR-7831 (sotrovimab) and COV2-2196/COV2-2130 (AstraZeneca), show reduced effectiveness due to the high mutation rate of the S protein in new variants [13]. Effective management of SARS-CoV-2 transmission requires public education and adherence to preventive measures [33]. Governments must provide clear and consistent updates on COVID-19 to avoid confusion [34]. Prophylactic measures, prevention strategies, and regular monitoring of patients' immune responses by healthcare professionals are critical for mitigating the pandemic [35]. Additionally, innovative approaches to creating safe healthcare environments for at-risk workers are essential.

Diagnosis and Diagnostic Tools

The transitional phase in COVID-19 management has resulted in significant shifts in infection control practices. The widespread use of hand sanitizers, aerosols, surface sterilizers, cleaning agents, PPE kits, face masks, and gloves has become a central aspect of public health measures [4]. This phase has also influenced health outcomes, particularly among vulnerable populations, while accelerating advancements in medical innovation, collaboration, and discovery. The pandemic has catalyzed progress in health and medicine, fostering new research opportunities in medical technology. This includes computational biology, gene sequencing, and the design and delivery of therapeutic antibodies and pharmaceutical interventions [14, 36]. The emergence and rapid spread of SARS-CoV-2 have posed a severe global public health challenge. Reliable and efficient diagnostic testing is essential for confirming infections. Current diagnostic methods encompass clinical imaging techniques, such as chest computed tomography (CT) scans and X-rays, as well as laboratory-based tests, including nucleic acid-based RT-PCR, RT-LAMP, and qRT-PCR assays [36, 37]. Additional approaches involve protein testing, point-of-care diagnostics, and fluorescence-based biosensors. Chest X-rays remain a primary imaging modality for evaluating cardiothoracic and pulmonary conditions, playing a crucial role in diagnosing COVID-19-associated pneumonia and assessing its severity [38]. Studies indicate that CT scans of COVID-19 patients exhibit distinct imaging patterns characterized by multilobar involvement and abnormal peripheral distribution [39, 40, 41]. Molecular diagnostic techniques, such as nucleic acid testing, rely on reverse transcriptase-polymerase chain reaction (RT-PCR), wherein retroviral DNA polymerase facilitates the conversion of viral RNA into complementary DNA (cDNA), followed by PCR amplification of target genetic regions [42]. RT-qPCR is a highly specific and rapid molecular assay capable of detecting even trace amounts of viral genetic material [43]. Additionally, this method can quantify minimal antibody concentrations from diverse sample types [44]. The World Health Organization (WHO) has approved specific testing methodologies for laboratory use. Fluorescence-based biosensors have also been introduced for cost-effective and rapid detection of antibodies in serum samples [45].

The effectiveness of diagnostic techniques can be optimized through the integration of multiple methodologies. For instance, the combined RT-LAMP and CRISPR-Cas12 system offers a simple, rapid, and efficient diagnostic approach when developed as a portable testing kit [46]. Advances in medical technology continue to refine diagnostic techniques, enhancing their reliability, accuracy, user-friendliness, and cost-efficiency. These improvements aim to ensure widespread accessibility, regardless of socioeconomic constraints. Rapid diagnostic tests primarily detect antibodies produced in response to viral exposure or, alternatively, antigenic viral proteins present in patient samples. These tests offer affordability

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13915 – 13928
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6521

and immediate results but exhibit limitations in sensitivity and the potential for false-negative outcomes. The RT-PCR technique employs reverse transcriptase to amplify specific genetic fragments, with initial cDNA synthesis followed by PCR amplification. This method ensures high sensitivity and specificity, yet it requires expensive laboratory equipment, specialized personnel, and extended processing time. Despite its drawbacks, RT-PCR remains the gold standard for SARS-CoV-2 detection due to its superior diagnostic performance compared to other nucleic acid-based assays.

The RT-LAMP assay utilizes four to six primers that selectively bind to six regions of the target DNA, significantly reducing viral detection time when performed with one-step reverse transcription. This method does not require sophisticated equipment and provides results within 30 minutes. However, it remains under development and is susceptible to false-positive results due to carry-over contamination [46]. RT-qPCR employs SARS-CoV-2-specific primers and probes that bind within amplified target sequences, leading to fluorescence emission upon probe degradation by Taq polymerase. This highly specific technique detects even minimal viral fragments, but its reliability depends on standardized measurement protocols. It also demands high-cost reagents and instrumentation. The SARS-CoV-2 R-GENE Kit, which includes RNA-dependent RNA polymerase primers, has demonstrated sensitivity ranging from 60.2% to 97.9%.

The CRISPR-Cas12-based assay targets the E and N gene sequences of SARS-CoV-2, cleaving specific sequences to generate easily interpretable colorimetric results. While highly sensitive and specific, limited standardized assays are currently available [46]. High-resolution computed tomography (HRCT) is a non-invasive imaging modality that generates cross-sectional chest images through multiple X-ray acquisitions. This method provides efficient and reliable assessments but necessitates specialized personnel for interpretation, involves high costs, and exposes patients to ionizing radiation. Furthermore, while HRCT assists in COVID-19 screening, it does not independently confirm infection. During the early stages of the pandemic, numerous diagnostic companies actively engaged in the research, development, validation, verification, and distribution of diagnostic assays. Hundreds of molecular tests and immunoassays were rapidly introduced, though many remain pending regulatory approval. The refinement of diagnostic methods, extensive molecular epidemiological validation, and official certification by regulatory bodies such as the FDA are still necessary. Furthermore, limitations persist regarding the availability of biobank data and long-term patient follow-up.

Artificial intelligence (AI) and machine learning have emerged as essential tools for data interpretation in COVID-19 diagnostics. To combat current and future pandemics, global collaboration is imperative to ensure widespread diagnostic test availability, effective infectious disease control, and strategic diagnostic implementation. Clinicians must be equipped to make informed therapeutic decisions and monitor treatment efficacy. While deep learning algorithms integrated with imaging techniques provide valuable insights, they cannot fully replace the role of physicians in clinical diagnosis. The current research landscape suggests that AI experts must collaborate with radiologists and healthcare professionals to enhance diagnostic support systems for early COVID-19 detection and severity assessment. Recent findings indicate that the PCR-based Automatic Integrated Gene Detection System (AIGS) RNA detection kit can be employed to identify Omicron variant sublineages in respiratory tract samples. This assay demonstrates a detection rate of approximately 95.1% for Omicron variants, including BA.1 through BA.5 [47]. Such diagnostic advancements facilitate the identification of infected individuals and aid in epidemiological tracking. The presence of SARS-CoV-2 nucleocapsid-specific antibodies serves as an early diagnostic biomarker. Additionally, novel biotechnological tools utilizing functionalized magnetic microbeads coated with recombinant spike (S) and nucleocapsid (N) proteins have been developed to quantitatively assess SARS-CoV-2 immunoglobulins in infected and non-infected individuals [48].

Prophylactic Measures

Currently, only a few standard drugs have received recent FDA approval in the USA. However, drug repurposes presents an effective and immediate strategy for combating the disease. Available treatments primarily consist of small-molecule drugs that either inhibit viral entry into host cells or disrupt viral assembly and replication [13, 49,50,51,52,53]. Research findings indicate that remdesivir reduces the recovery time of hospitalized patients, consequently lowering mortality rates [54]. Beigel et al. conducted a

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13915 – 13928
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6521

study involving 1,062 patients, with 541 receiving remdesivir and 521 placed in the placebo group. Evidence suggests that patients under standard treatment had an average hospitalization period of 15 days, whereas those administered remdesivir experienced a shorter hospitalization period of 11 days [55]. Chu et al. evaluated the efficacy of Lopinavir/Ritonavir in 41 COVID-19 patients over three weeks. Clinical data indicated that the treatment group experienced fewer adverse effects compared to the control group. Moreover, patients treated with the Lopinavir/Ritonavir combination exhibited a lower infection rate and reduced steroid dependency. This treatment approach resulted in decreased viral load and increased blood cell count, promoting positive outcomes and faster recovery [56].

Arbidol demonstrated superior efficacy compared to lopinavir, as evidenced by meta-analysis studies showing a significant SARS-CoV-2 nucleic acid conversion rate on day 7 ($p = 0.03$) and day 14 ($p = 0.006$). Additionally, Arbidol treatment correlated with a higher improvement rate on day 14 ($p = 0.02$) and a lower mortality rate ($p = 0.007$) [57]. Mehra et al. analyzed the effectiveness of chloroquine, both alone and in combination with a macrolide. The study included 96,032 hospitalized COVID-19 patients, with 14,888 receiving treatment and 81,144 serving as controls. Among the treated patients, 1,868 and 3,016 were administered chloroquine and hydroxychloroquine alone, while 3,782 and 6,221 received these drugs in combination with a macrolide. Unfortunately, the results indicated that these treatments reduced survival rates and increased the incidence of arrhythmias. Cathrine et al., in randomized trials, found that hydroxychloroquine increased the mortality risk in COVID-19 patients and that chloroquine provided no significant benefit [58]. Recent studies suggest that favipiravir can reduce inflammatory mediators but does not fully restore respiratory function. SARS-CoV-2-induced respiratory distress is hypothesized to result from both direct viral activity and inflammatory chemical mediators. Some patients continued to experience inflammation and cytokine storms after favipiravir therapy, though these were manageable with steroid administration [59].

Molnupiravir has received FDA approval for COVID-19 treatment [60]. It is an oral bioavailable ribonucleoside analog of B-D-N4-Hydroxycytidine [61], functioning as an antiviral agent with broad-spectrum activity against RNA viruses. Molnupiravir inhibits viral replication and has demonstrated effectiveness in reducing nasopharyngeal viral load. Its prodrug form, B-D-N4-Hydroxycytidine-5-Isopropyl ester (EIDD1931), integrates into the viral genome, replacing uracil or cytosine, thereby inducing mutations that result in replication errors [50]. Studies confirm that molnupiravir is effective against various influenza and coronavirus strains [62]. Phase I/II/III trials have shown that molnupiravir reduces the risk of hospitalization and death in mild COVID-19 cases. Animal studies revealed that administering molnupiravir to humanized mouse models significantly decreased in vivo viral replication and SARS-CoV-2 symptoms [63]. A cohort study conducted during an omicron BA.2-dominated pandemic wave by Wong et al. assessed the virological impact of molnupiravir and nirmatrelvir–ritonavir in hospitalized patients with mild-to-moderate COVID-19. Among 40,776 patients, 1,856 received molnupiravir. Results indicated that molnupiravir treatment significantly reduced all-cause mortality. Compared to untreated patients, those receiving molnupiravir or nirmatrelvir–ritonavir exhibited a lower risk of disease progression, reduced oxygen therapy requirements, and lower mortality rates [64]. The decline in mortality was particularly evident among high-risk hospitalized patients, including those over 80 years old [65]. The study also administered Paxlovid to 890 patients, demonstrating its effectiveness in lowering mortality rates [64]. Paxlovid consists of nilmatrelvir, a second-generation protease inhibitor, combined with ritonavir, a pharmacological enhancer. This combination inhibits viral replication, exhibiting strong antiviral activity against SARS-CoV-2 [66].

Biological therapies include polyclonal antibodies (pAbs), monoclonal antibodies (mAbs), convalescent plasma, and hyperimmune γ-globulin, all of which serve as passive immunotherapy for COVID-19 treatment [67]. Some repurposed mAbs are used in hospitalized patients aged 12 years and older, including bamlanivimab–etesevimab, casirivimab–imdevimab, and sotrovimab. These mAbs neutralize viral proteins and regulate cytokine levels. However, mAb therapy is not administered to hospitalized patients with hypoxia. The key drugs used in COVID-19 treatment are summarized in Table 2. Research continues on developing SARS-CoV-2-specific antivirals and monoclonal antibodies, with several undergoing clinical trials. Neutralizing mAbs provide rapid passive immunization, reducing viral load and modulating immune

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13915 – 13928
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6521

responses. Monoclonal antibodies also elicit immune activation. Clinical studies are currently evaluating ruvalizumab, a recombinant monoclonal antibody targeting complement system (CS) proteins, which exhibits anti-inflammatory properties. Other mAbs under clinical investigation include AK119, JMB2002, LY-CoVMab, ADM03820, HLX70, and DXP604. The USFDA has granted emergency use authorization for certain mAbs, including tocilizumab (TCZ), regdanvimab (CT-P59), sotrivimab (VIR-7831), SCT-401, and levilimab. Additionally, some mAbs demonstrate efficacy against multiple SARS-CoV-2 variants, including alpha, beta, gamma, delta, and omicron. These include sotrovimab, tixagevimab plus cilgavimab, casirivimab, and imdevimab [67].

Vaccination

Immunization is crucial for disease prevention and containment. To control the COVID-19 pandemic, a significant portion of the global population must be vaccinated. As per recent data, 66.8% of the world's population has received at least one dose of a COVID-19 vaccine, with a total of 12.15 billion doses administered worldwide [68]. Various vaccines have been developed, including mRNA-based vaccines, which introduce mRNA sequences for disease-specific antigens. Additionally, DNA-based, attenuated, and vector-based vaccines have emerged as promising alternatives due to their cost-effectiveness and rapid production. Figure 1 illustrates different vaccine types. Veterinary vaccines have also been approved in some regions to curb virus transmission from domestic animals [69]. The inactivated vaccine contains whole virus particles that have been neutralized using heat or chemicals like formaldehyde or formalin. This process eliminates the virus's ability to replicate while preserving epitopes to trigger an immune response [70]. Attenuated vaccines involve weakened or modified live pathogens capable of replicating within the body, generating a prolonged immune response. Subunit vaccines employ only specific antigenic components to stimulate immunity. Other vaccine categories include toxoid vaccines, conjugated vaccines, and nucleic acid vaccines such as RNA and DNA-based vaccines, which use genetic material to produce antigenic molecules resembling those of pathogenic organisms [71].

The US Food and Drug Administration (FDA) has fully authorized the Pfizer/BioNTech vaccine for human use, while 38 other vaccine candidates remain under emergency use authorization [72]. Approximately 60% of the global population, equating to nearly 12 billion vaccine doses, has received at least a single dose as of May 2022. Given the expedited regulatory pathways for SARS-CoV-2 vaccines, vaccinovigilance (Phase 4 clinical trials) and the establishment of comprehensive vaccination programs are vital for safeguarding public health. Vaccination remains the most effective strategy against COVID-19. The US FDA recently authorized limited use of the Johnson & Johnson (J&J) COVID-19 vaccine for individuals aged 18 and above who either lack access to approved vaccines or opt for J&J instead [73]. Currently, 7.7% of the US population has received the J&J vaccine. Reports highlight safety concerns, particularly regarding rare blood clotting events associated with adenovirus-based vaccines [74]. This condition arises due to an immune response that forms aggregates between adenovirus and platelet factor 4, which antibodies bind to, leading to platelet activation. This chain of events culminates in thrombosis with thrombocytopenia syndrome, a severe health risk. Similar adverse reactions have been reported with vaccines such as AZD122, including skin rashes, vesicular plaque formation, muscle weakness, pitting edema in hands and feet, and neuropathic pain [75]. FDA officials have reviewed these incidents by analyzing post-vaccination adverse event reports and evaluating vaccine safety and efficacy data.

There is a surge in clinical research on mRNA vaccines, particularly in addressing infectious diseases. The demonstrated effectiveness of mRNA-based COVID-19 vaccines has driven industry interest in their potential applications for oncology, autoimmune disorders, and neurodegenerative diseases. Compared to earlier SARS-CoV-2 strains, the Omicron (B.1.1.529) variant exhibits heightened transmissibility and infectiousness [76]. Recipients of the Ad26.COV2.S or BNT162b2 vaccines developed durable spike-specific CD8+ and CD4+ T cell responses, which showed substantial cross-reactivity against both Delta and Omicron variants [77]. Multiple vaccine doses have proven effective in eliciting immune responses against different virus variants. A booster dose is recommended to enhance immunity when the initial protection declines. Researchers argue that Omicron presents a significant challenge to the two-dose vaccination strategy, leading to a 17–22-fold reduction in neutralization titers [78]. Several mRNA vaccines are commercially available, with studies evaluating their effectiveness. Muik et al. examined the efficacy of

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13915 – 13928
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6521

the BioNTech/Pfizer BNT162b2 mRNA vaccine against Omicron, concluding that three doses were necessary for adequate protection [76]. In December 2020, the Alpha variant (B.1.1.7) was classified as a variant of concern due to its 17 genetic mutations, which contributed to increased transmissibility [79, 80]. The Beta variant (B.1.351), identified in South Africa in May 2020, contained three mutations in the receptor-binding domain (RBD). More recently, the Omicron variant (B.1.1.529) has been detected in multiple countries since November 2021. This variant carries additional mutations within the RBD, further complicating containment efforts [81]. The World Health Organization (WHO) has approved multiple vaccines for emergency use, classified by their manufacturers and mechanisms of action. Table 3 presents details on the approved COVID-19 vaccines.

Lauring et al. conducted research to compare the effectiveness of mRNA vaccines and assess the clinical severity of COVID-19 cases associated with different variants. A study involving 11,690 participants demonstrated that mRNA vaccines exhibited effectiveness rates of 85% against the Alpha variant, 94% against Delta, and 65% against Omicron. Their findings indicate that mRNA vaccines provide substantial protection across various coronavirus strains, resulting in reduced disease severity among vaccinated individuals [82]. In January 2021, Indian drug regulators granted emergency approval for Covishield, a COVID-19 vaccine developed by AstraZeneca and the University of Oxford. Mahadevaiah et al. assessed the immunogenicity, safety, and efficacy of the Covishield vaccine, reporting a seropositivity rate of 69.67%, which falls within an acceptable safety threshold [83]. Another study on the BNT162b2 mRNA vaccine involved a Phase III clinical trial with 43,548 participants. Among 17,411 individuals who received the vaccine, eight cases of COVID-19 were recorded, whereas 162 cases were identified among 17,511 unvaccinated participants, demonstrating a vaccine efficacy of 95% [84]. Further analysis showed BNT162b2 had an efficacy rate of 95.6% among individuals aged 16–55 years. Among older groups, efficacy rates were 93.7% for individuals aged 55+, 94.7% for those aged 65+, and 100% for those aged 75 and above. Lindsey conducted a Phase III trial in the US across 99 centers to evaluate mRNA vaccine efficacy and safety. This study enrolled 30,420 individuals, who were randomly assigned to receive either the vaccine or a placebo in a 1:1 ratio. The results demonstrated a 94.1% efficacy rate in preventing COVID-19 infections [85].

Impact on Children, Pregnant Women, and the Elderly

The SARS-CoV-2 virus, responsible for COVID-19, affects individuals across all age groups, but variations in disease severity exist. The symptoms observed in children resemble those in adults and include fever, cough, sore throat, fatigue, nasal discharge, vomiting, nausea, body pain, and diarrhea [86]. A key observation is that most infected children remain asymptomatic. Despite showing mild or no symptoms, they act as carriers, facilitating transmission to more vulnerable age groups [87]. However, children with pre-existing conditions such as cancer, chronic pulmonary or cardiac diseases, neurological disorders, immunodeficiencies, or cardiovascular diseases are at higher risk of severe illness [87, 88]. While infections in children are generally mild compared to adults, infants tend to experience more severe cases when exposed to the virus [87, 89]. One serious complication in children infected with COVID-19 is multisystem inflammatory syndrome [88]. As the virus transitions from a pandemic to an endemic phase, it is expected that a higher proportion of children will contract SARS-CoV-2, similar to other epidemic coronaviruses [90]. Pregnant women who develop symptoms of COVID-19 are more prone to severe illness, which may result in adverse maternal and neonatal outcomes such as preterm birth or fetal distress during labor [91, 92]. However, asymptomatic pregnant women with COVID-19 exhibit complications comparable to those of non-infected individuals [92]. The emergence of highly transmissible variants poses additional risks to both expecting mothers and neonates, making vaccination and immunization a crucial preventive measure [93]. Aging is associated with immunosenescence, a decline in immune system function, while also being linked to chronic inflammation due to increased production of inflammatory mediators and cytokines [94]. Individuals aged 65 and older face higher mortality rates and increased hospitalization rates due to SARS-CoV-2 infection [95, 96]. Underlying chronic conditions, including cardiovascular diseases, diabetes, and obesity, further elevate their susceptibility to severe illness [96].

Patients who are immunocompromised or have pre-existing medical conditions face a significantly higher risk of mortality and complications if hospitalized with COVID-19 [97, 98]. Infection can exacerbate their

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13915 – 13928
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6521

primary health conditions, leading to further deterioration [97]. These individuals are more likely to require intensive care unit (ICU) admission and have a higher probability of death. This high-risk category includes those with cancer, hematopoietic cell transplants, solid organ transplants, diabetes mellitus, and hypertension [97, 99]. Regardless of age, disease progression in immunocompromised patients is often rapid and severe (Fig. 2) [99]. Protecting these vulnerable groups remains a critical concern. Basic differences explaining the variations in the impact of infections in the three population categories Certain monoclonal antibody treatments, including bamlanivimab–etesevimab, casirivimab–imdevimab, and sotrovimab, have been granted emergency use authorization for individuals with at least two risk factors. These risk factors include age above 65, pregnancy, immunocompromised status, and chronic conditions such as hypertension, diabetes, and obesity [67]. Additionally, molnupiravir has been approved for treating high-risk patients, including older adults and individuals with chronic illnesses. However, its use is not recommended for pregnant or breastfeeding women and children [100]. The U.S. Food and Drug Administration (USFDA) has authorized the use of the Moderna and Pfizer-BioNTech COVID-19 vaccines for children as young as six months in emergency situations [101].

Role of Social Services, and Industrial Security in COVID-19 Pandemic

The COVID-19 pandemic exposed significant vulnerabilities in public health systems, economic structures, and social welfare programs. Social services and industrial security played crucial roles in mitigating the crisis by ensuring public well-being, maintaining workplace safety, and supporting economic stability. Their coordinated efforts helped manage social disruptions, enforce safety measures, and protect vulnerable populations.

Role of Social Services

Social services were instrumental in addressing the immediate and long-term effects of the pandemic. Their role encompassed various aspects, including healthcare support, financial assistance, mental health services, and community outreach.

- Healthcare and Essential Aid: Social workers collaborated with healthcare professionals to facilitate access to medical services, particularly for marginalized groups. They helped coordinate testing, vaccination campaigns, and delivery of medical supplies to communities with limited healthcare infrastructure. Additionally, they supported individuals who were homebound due to illness or quarantine restrictions, ensuring they had access to food, medicine, and other essential supplies.

- Financial and Employment Assistance: The pandemic led to widespread economic hardships, including job losses and reduced incomes. Social services provided financial aid programs, including unemployment benefits, food assistance, and emergency housing support. Government and non-governmental organizations (NGOs) played a key role in distributing financial relief packages to individuals and businesses affected by lockdowns and economic slowdowns.

- Mental Health Support: The crisis increased stress, anxiety, and depression due to social isolation, fear of infection, and economic uncertainty. Social workers and mental health professionals provided counseling services, crisis intervention, and online support groups to help individuals cope with the psychological impact of the pandemic. Special attention was given to healthcare workers, frontline responders, and individuals who lost loved ones.

- Protection of Vulnerable Groups: Children, elderly individuals, persons with disabilities, and homeless populations faced greater risks during the pandemic. Social services ensured their safety by implementing protection programs, including emergency shelters, domestic violence interventions, and home-care assistance for senior citizens. Educational initiatives also helped mitigate the impact of school closures by providing remote learning support and internet access to low-income families.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13915 – 13928
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6521

Industrial security played a vital role in maintaining workplace safety, preventing virus transmission, and protecting critical infrastructure during the pandemic. Organizations had to adapt quickly to new health and safety regulations to ensure business continuity and safeguard employees.

- Workplace Safety and Health Protocols: Industrial security teams implemented stringent measures to prevent workplace outbreaks. These included temperature screenings, social distancing policies, personal protective equipment (PPE) distribution, and regular sanitization of workspaces. Many organizations adopted remote work policies to minimize in-person interactions while maintaining operational efficiency.

- Supply Chain and Logistics Security: The pandemic disrupted global supply chains, causing shortages of medical equipment, food, and essential goods. Industrial security teams worked to protect logistics networks from theft, fraud, and cyberattacks. They also ensured the safe transportation and storage of vaccines and medical supplies, preventing distribution bottlenecks.

- Cybersecurity and Data Protection: With the shift to remote work and digital operations, cybersecurity became a major concern. Industrial security professionals enhanced network protections against cyber threats, including phishing attacks, ransomware, and data breaches. Companies implemented stricter access controls, encryption methods, and employee cybersecurity training to mitigate risks.

- Crisis Management and Emergency Response: Many industries had to develop and implement emergency response plans to handle pandemic-related disruptions. Industrial security teams worked alongside public health officials to enforce quarantine measures, manage crowd control, and prevent unauthorized access to restricted areas. In high-risk sectors such as healthcare and manufacturing, security personnel ensured compliance with evolving regulations. Social services and industrial security were essential in managing the COVID-19 crisis. Social services provided critical support for healthcare access, financial aid, mental health, and vulnerable populations. Industrial security ensured workplace safety, supply chain integrity, cybersecurity, and crisis management. Their combined efforts helped mitigate the pandemic's impact, protect public welfare, and maintain economic stability. Strengthening these sectors will be crucial in preparing for future health emergencies and safeguarding society against similar crises.

Conclusion

The COVID-19 pandemic has been a stark reminder of the interconnectedness of global health, socio-economic systems, and industrial infrastructure. The rapid spread of SARS-CoV-2 and its evolving variants have necessitated an interdisciplinary approach to manage the crisis effectively. This article has highlighted the critical roles of emergency care, laboratory diagnostics, pharmaceutical management, social services, and industrial security in combating the pandemic. Diagnostic advancements have been pivotal in identifying and tracking COVID-19 cases. Techniques such as RT-PCR, RT-LAMP, and CRISPR-Cas12 have enhanced the accuracy and speed of detection, enabling timely interventions. Therapeutic strategies, including the use of monoclonal antibodies and antiviral drugs like molnupiravir, have shown promise in reducing severe outcomes and mortality rates. Vaccination campaigns have been instrumental in controlling the spread of the virus, with mRNA vaccines demonstrating high efficacy against multiple variants, including Delta and Omicron. Social services have played a crucial role in mitigating the socio-economic impact of the pandemic. From providing healthcare access and financial aid to offering mental health support and protecting vulnerable populations, social workers have been at the forefront of the crisis response. Industrial security measures have ensured workplace safety, maintained supply chain integrity, and protected critical infrastructure, thereby supporting economic stability during unprecedented disruptions. The pandemic has also underscored the importance of global collaboration and innovation. The rapid development and deployment of vaccines, the repurposing of existing drugs, and the integration of advanced diagnostic tools exemplify the power of scientific and technological advancements in addressing

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13915 – 13928
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6521

public health emergencies. However, challenges such as vaccine hesitancy, healthcare disparities, and the emergence of new variants highlight the need for continued vigilance and adaptive strategies. In conclusion, the COVID-19 pandemic has demonstrated the necessity of a holistic, interdisciplinary approach to manage global health crises. Strengthening healthcare systems, enhancing social services, and ensuring industrial security are essential for mitigating the impact of the current pandemic and preparing for future challenges. By fostering collaboration across sectors and leveraging scientific advancements, we can build a more resilient global community capable of responding effectively to emerging threats.

References

Chavda VP, Patel AB, Vihol D, Vaghasiya DD, Ahmed KMSB, Trivedi KU, et al. Herbal remedies, nutraceuticals, and dietary supplements for COVID-19 management: an update. Clin Complement Med Pharmacol. 2022. https://doi.org/10.1016/j.ccmp.2022.100021.

Chavda VP, Bezbaruah R, Athalye M, Parikh PK, Chhipa AS, Patel S, et al. Replicating viral vector-based vaccines for COVID-19: potential avenue in vaccination arena. Viruses. 2022. https://doi.org/10.3390/v14040759.

Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182:812-827.e19. https://doi.org/10.1016/J.CELL.2020.06.043.

Chavda VP, Sonak SS, Munshi NK, Dhamade PN. Pseudoscience and fraudulent products for COVID-19 management. Environ Sci Pollut Res Int. 2022. https://doi.org/10.1007/s11356-022-21967-4.

Upshaw TL, Brown C, Smith R, Perri M, Ziegler C, Pinto AD. Social determinants of COVID-19 incidence and outcomes: a rapid review. PLoS One. 2021;16: e0248336. https://doi.org/10.1371/JOURNAL.PONE.0248336.

Paremoer L, Nandi S, Serag H, Baum F. Covid-19 pandemic and the social determinants of health. BMJ. 2021. https://doi.org/10.1136/BMJ.N129.

Chavda VP, Apostolopoulos V. Rare monkeypox: is it really a threat to the elderly? Maturitas. 2022. https://doi.org/10.1016/j.maturitas.2022.05.014.

Chavda VP, Vora LK, Apostolopoulos V. Monkeypox: a new face of outbreak. Expert Rev Vaccines. 2022. https://doi.org/10.1080/14760584.2022.2113515.

Severe acute hepatitis of unknown aetiology in children - Multi-country n.d. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON394. Accessed 4 Sept 2022

Weaver AK, Head JR, Gould CF, Carlton EJ, Remais JV. Environmental factors influencing COVID-19 incidence and severity. Annu Rev Public Health. 2022;43:271–91. https://doi.org/10.1146/ANNUREV-PUBLHEALTH-052120-101420.

SARS-CoV-2 Variant Classifications and Definitions n.d. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html. Accessed 8 Sept 2022

Vivek P. Chavda. Omicron variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly? 2020.

Chavda VP, Hanuma Kumar Ghali EN, Yallapu MM. Apostolopoulos V. therapeutics to tackle omicron outbreak. Immunotherapy. 2022. https://doi.org/10.2217/imt-2022-0064.

Chavda VP, Patel AB, Vaghasiya DD. SARS-CoV-2 variants and vulnerability at the global level. J Med Virol. 2022;94:2986–3005. https://doi.org/10.1002/jmv.27717.

Basit A, Ali T, Ur Rehman S. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent. J Biomol Struct Dyn. 2020. https://doi.org/10.1080/07391102.2020.1768150.

Peacock TP, Brown JC, Zhou J, Thakur N, Newman J, Kugathasan R, et al. The SARS-CoV-2 variant, omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. BioRxiv. 2022. https://doi.org/10.1101/2021.12.31.474653.

Willett BJ, Grove J, MacLean OA, Wilkie C, De Lorenzo G, Furnon W, et al. SARS-CoV-2 omicron is an immune escape variant with an altered cell entry pathway. Nat Microbiol. 2022;7:1161–79. https://doi.org/10.1038/s41564-022-01143-7.

Weekly epidemiological update on COVID-19 - 31 August 2022 n.d. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---31-august-2022. Accessed 8 Sept 2022

V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19:155–70. https://doi.org/10.1038/s41579-020-00468-6.

Jones AN, Mourão A, Czarna A, Matsuda A, Fino R, Pyrc K, et al. Characterization of SARS-CoV-2 replication complex elongation and proofreading activity. Sci Rep. 2022;12:1–9. https://doi.org/10.1038/s41598-022-13380-1.

Manzanares-Meza LD, Medina-Contreras O. SARS-CoV-2 and influenza: a comparative overview and treatment implications. Bol Med Hosp Infant Mex. 2020;77:262–73. https://doi.org/10.24875/BMHIM.20000183.

Chavda VP, Chen Y, Dave J, Chen Z-S, Chauhan SC, Yallapu MM, et al. COVID-19 and vaccination: myths vs science. Expert Rev Vaccines. 2022. https://doi.org/10.1080/14760584.2022.2114900.

Rahimi F, TalebiBezmin Abadi A. Hybrid SARS-CoV-2 variants. Int J Surg. 2022. https://doi.org/10.1016/J.IJSU.2022.106656.

Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021;22:757. https://doi.org/10.1038/S41576-021-00408-X.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13915 – 13928
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6521

Amoutzias GD, Nikolaidis M, Tryfonopoulou E, Chlichlia K, Markoulatos P, Oliver SG. The remarkable evolutionary plasticity of coronaviruses by mutation and recombination: insights for the COVID-19 pandemic and the future evolutionary paths of SARS-CoV-2. Viruses. 2022;14:78. https://doi.org/10.3390/v14010078.

Beloukas A, Rampias T. Biological and clinical significance of adaptive evolution of coronaviruses. Life. 2021. https://doi.org/10.3390/LIFE11111129.

Rathnasinghe R, Jangra S, Ye C, Cupic A, Singh G, Martínez-Romero C, et al. Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera. Nat Commun. 2022;13:1–14. https://doi.org/10.1038/s41467-022-30763-0.

Novelli G, Colona V, Pandolfi P. A focus on the spread of the delta variant of SARS-CoV-2 in India. Indian J Med Res. 2021;153:537–41. https://doi.org/10.4103/IJMR.IJMR_1353_21.

Chavda VP. Apostolopoulos V. Global impact of delta plus variant and vaccination. Expert Rev Vaccines. 2022. https://doi.org/10.1080/14760584.2022.2044800.

Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G. Omicron and delta variant of SARS-CoV-2: a comparative computational study of spike protein. J Med Virol. 2022;94:1641–9. https://doi.org/10.1002/JMV.27526.

Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, et al. Genomewide association study of severe covid-19 with respiratory failure. N Engl J Med. 2020;383:1522–34. https://doi.org/10.1056/NEJMOA2020283.

Callaway E. What omicron's BA.4 and BA.5 variants mean for the pandemic. Nature. 2022. https://doi.org/10.1038/D41586-022-01730-Y.

Prakash V, Rajpurohit D, Suneetha V. Currency as a new mode of transmission of pathogens. Res J Pharm Biol Chem Sci. 2016;7:157–63. https://doi.org/10.14299/IJSER.2014.08.002.

Ciotti M, Ciccozzi M, Terrinoni A, Jiang W-C, Wang C-B, Bernardini S. The COVID-19 pandemic. Crit Rev Clin Lab Sci. 2020;57:365–88. https://doi.org/10.1080/10408363.2020.1783198.

Vijayasarathy S, Suneetha V. Un-noticed infections that affects public health: a brief study. Int J Res Pharm Sci. 2020;11:1343–7. https://doi.org/10.26452/IJRPS.V11I2.1995.

Krishnan A, Gangadaran P, Chavda VP, Jogalekar MP, Muthusamy R, Valu D, et al. Convalescent serum-derived exosomes: attractive niche as COVID-19 diagnostic tool and vehicle for mRNA delivery. Exp Biol Med (Maywood). 2022. https://doi.org/10.1177/15353702221092984.

Vandenberg O, Martiny D, Rochas O, van Belkum A, Kozlakidis Z. Considerations for diagnostic COVID-19 tests. Nat Rev Microbiol. 2021;19:171

Raoof S, Feigin D, Sung A, Raoof S, Irugulpati L, Rosenow EC. Interpretation of plain chest roentgenogram. Chest. 2012;141:545–58. https://doi.org/10.1378/CHEST.10-1302.

Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20:425–34. https://doi.org/10.1016/S1473-3099(20)30086-4.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33. https://doi.org/10.1056/NEJMOA2001017.

Ufuk F. Three-dimensional CT of COVID-19 pneumonia. Radiology. 2020;296:E180. https://doi.org/10.1148/RADIOL.2020201183.

Freeman WM, Walker SJ, Vrana KE. Quantitative RT-PCR: pitfalls and potential. Biotechniqu. 1999;26:112–25. https://doi.org/10.2144/99261RV01.

Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eur Surv. 2019. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.

Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611–22. https://doi.org/10.1373/CLINCHEM.2008.112797.

Elledge SK, Zhou XX, Byrnes JR, Martinko AJ, Lui I, Pance K, et al. Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection. Nat Biotechnol. 2021;39:928–35. https://doi.org/10.1038/S41587-021-00878-8.

Teymouri M, Mollazadeh S, Mortazavi H, NaderiGhale-noie Z, Keyvani V, Aghababaei F, et al. Recent advances and challenges of RT-PCR tests for the diagnosis of COVID-19. Pathol Res Pract. 2021;221: 153443. https://doi.org/10.1016/J.PRP.2021.153443.

Ippoliti C, De Maio F, Santarelli G, Marchetti S, Vella A, Santangelo R, et al. Rapid detection of the omicron (B.1.1.529) SARS-CoV-2 variant using a COVID-19 diagnostic PCR assay. Microbiol Spectr. 2022. https://doi.org/10.1128/spectrum.00990-22.

Torrente-Rodríguez RM, Montero-Calle A, San Bartolomé C, Cano O, Vázquez M, Iglesias-Caballero M, et al. Towards control and oversight of SARS-CoV-2 diagnosis and monitoring through multiplexed quantitative electroanalytical immune response biosensors. Angew Chem. 2022. https://doi.org/10.1002/ange.202203662.

Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–93. https://doi.org/10.1001/JAMA.2020.12839.

Basu D, Chavda VP, Mehta AA. Therapeutics for COVID-19 and post COVID-19 complications: an update. Curr Res Pharmacol Drug Discov. 2022. https://doi.org/10.1016/j.crphar.2022.100086.

Chavda VP, Gajjar N, Shah N, Dave DJ. Darunavir ethanolate: repurposing an anti-HIV drug in COVID-19 treatment. Eur J Med Chem Rep. 2021;3:100013. https://doi.org/10.1016/j.ejmcr.2021.100013.

Chavda VP, Kapadia C, Soni S, Prajapati R, Chauhan SC, Yallapu MM, et al. A global picture: therapeutic perspectives for COVID-19. Immunotherapy. 2022. https://doi.org/10.2217/imt-2021-0168.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13915 – 13928
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6521

Huang Z, Chavda VP, Vora LK, Gajjar N, Apostolopoulos V, Shah N, et al. 2-Deoxy-D-glucose and its derivatives for the COVID-19 treatment: an update. Front Pharmacol. 2022;13: 899633. https://doi.org/10.3389/fphar.2022.899633.

Angamo MT, Mohammed MA, Peterson GM. Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis. Infection. 2022;50:27–41. https://doi.org/10.1007/S15010-021-01671-0.

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of covid-19 — final report. N Engl J Med. 2020;383:1813–26. https://doi.org/10.1056/NEJMOA2007764/SUPPL_FILE/NEJMOA2007764_DATA-SHARING.PDF.

Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252–6. https://doi.org/10.1136/THORAX.2003.012658.

Yu M, Wang DC, Li S, Lei YH, Wei J, Huang LY. Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019. J Med Virol. 2022;94:1513–22. https://doi.org/10.1002/JMV.27481.

Axfors C, Schmitt AM, Janiaud P, van't Hooft J, Abd-Elsalam S, Abdo EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021;12:1–13. https://doi.org/10.1038/s41467-021-22446-z.

Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021;102:501–8. https://doi.org/10.1016/j.ijid.2020.10.069.

Fischer W, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, et al. Molnupiravir, an oral antiviral treatment for COVID-19. MedRxiv Prepr Serv Heal Sci. 2021. https://doi.org/10.1101/2021.06.17.21258639.

Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and nirmatrelvir-ritonavir: oral COVID antiviral drugs. Clin Infect Dis. 2022. https://doi.org/10.1093/CID/CIAC180.

Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern. Antiviral Res. 2022;198: 105252. https://doi.org/10.1016/j.antiviral.2022.105252.

Wahl A, Gralinski LE, Johnson CE, Yao W, Kovarova M, Dinnon KH, et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021;591:451–7. https://doi.org/10.1038/S41586-021-03312-W.

Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022. https://doi.org/10.1016/S1473-3099(22)00507-2.

Flisiak R, Zarębska-Michaluk D, Rogalska M, Kryńska JA, Kowalska J, Dutkiewicz E, et al. Real-world experience with molnupiravir during the period of SARS-CoV-2 omicron variant dominance. Pharmacol Rep. 2022. https://doi.org/10.1007/S43440-022-00408-6.

Marzi M, Vakil MK, Bahmanyar M, Zarenezhad E. Paxlovid: mechanism of action, synthesis, and in silico study. Biomed Res Int. 2022;2022:7341493. https://doi.org/10.1155/2022/7341493.

Chavda VP, Prajapati R, Lathigara D, Nagar B, Kukadiya J, Redwan EM, et al. Therapeutic monoclonal antibodies for COVID-19 management: an update. Expert Opin Biol Ther. 2022. https://doi.org/10.1080/14712598.2022.2078160.

Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5:947–53. https://doi.org/10.1038/S41562-021-01122-8.

Chavda VP, Feehan J, Apostolopoulos V. A veterinary vaccine for SARS-CoV-2: the first COVID-19 vaccine for animals. Vaccines. 2021. https://doi.org/10.3390/vaccines9060631.

Chavda VP, Pandya R, Apostolopoulos V. DNA vaccines for SARS-CoV-2: toward third-generation vaccination era. Expert Rev Vaccines. 2021;20:1549–60. https://doi.org/10.1080/14760584.2021.1987223.

Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011;3:73. https://doi.org/10.4103/0974-777X.77299.

Vasireddy D, Atluri P, Malayala SV, Vanaparthy R, Mohan G. Review of COVID-19 vaccines approved in the United States of America for emergency use. J Clin Med Res. 2021;13:204–13. https://doi.org/10.14740/jocmr4490.

FDA Office of Media Affairs (2022) Coronavirus (COVID-19) update: FDA limits use of Janssen COVID-19 vaccine to certain individuals. FDA NEWS RELEASE 2022:For Immediate Release: May 05, 2022

Bernard NJ. Vaccine thrombosis. Nat Immunol. 2022;23:2. https://doi.org/10.1038/s41590-021-01111-z.

Capassoni M, Ketabchi S, Cassisa A, Caramelli R, Molinu AA, Galluccio F, et al. AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event: a case report. J Med Virol. 2021;93:5718. https://doi.org/10.1002/JMV.27175.

Muik A, Lui BG, Wallisch A-K, Bacher M, Mühl J, Reinholz J, et al. Neutralization of SARS-CoV-2 omicron by BNT162b2 mRNA vaccine-elicited human sera. Science (80-). 2022;375:678–80. https://doi.org/10.1126/science.abn7591.

Liu J, Chandrashekar A, Sellers D, Barrett J, Jacob-Dolan C, Lifton M, et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron. Nature. 2022;603:493–6. https://doi.org/10.1038/s41586-022-04465-y.

Chavda VP, Apostolopoulos V. Is booster dose strategy sufficient for omicron variant of SARS-CoV-2? Vaccines. 2022;10:1–6. https://doi.org/10.3390/vaccines10030367.

Burki T. Understanding variants of SARS-CoV-2. Lancet (London, England). 2021;397:462. https://doi.org/10.1016/S0140-6736(21)00298-1.

Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021;593:266–9. https://doi.org/10.1038/s41586-021-03470-x.

Tian D, Sun Y, Xu H, Ye Q. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 omicron variant. J Med Virol. 2022;94:2376–83. https://doi.org/10.1002/JMV.27643.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13915 – 13928
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6521

Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, Mcneal T, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022. https://doi.org/10.1136/BMJ-2021-069761.

Mahadevaiah A, Doddamadaiah C, Sadananda KS, Cholenahalli NM. Study of immunogenicity, safety and efficacy of covishield vaccine among health care workers in a tertiary cardiac care centre. Indian J Med Microbiol. 2022;40:200–3. https://doi.org/10.1016/J.IJMMB.2022.03.003.

Kwok HF. Review of covid-19 vaccine clinical trials - a puzzle with missing pieces. Int J Biol Sci. 2021;17:1461. https://doi.org/10.7150/IJBS.59170.

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16. https://doi.org/10.1056/NEJMOA2035389.

Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109:1088–95. https://doi.org/10.1111/apa.15270.

Çokuğraş H, Önal P. SARS-CoV-2 infection in children. Turkish Arch Pediatr Pediatr Arşivi. 2020;55:95. https://doi.org/10.14744/TURKPEDIATRIARS.2020.20270.

Bogunovic D, Merad M. Children and SARS-CoV-2. Cell Host Microbe. 2021;29:1040. https://doi.org/10.1016/J.CHOM.2021.06.015.

Liguoro I, Pilotto C, Bonanni M, Ferrari ME, Pusiol A, Nocerino A, et al. SARS-COV-2 infection in children and newborns: a systematic review. Eur J Pediatr. 2020;179:1029. https://doi.org/10.1007/S00431-020-03684-7.

Frutos AM, Kubale J, Kuan G, Ojeda S, Vydiswaran N, Sanchez N, et al. SARS-CoV-2 and endemic coronaviruses: comparing symptom presentation and severity of symptomatic illness among Nicaraguan children. PLOS Glob Public Heal. 2022;2: e0000414. https://doi.org/10.1371/JOURNAL.PGPH.0000414.

Gomez UT, Francisco RPV, Baptista FS, Gibelli MABC, Ibidi SM, de Carvalho WB, et al. Impact of SARS-CoV-2 on pregnancy and neonatal outcomes: an open prospective study of pregnant women in Brazil. Clinics (Sao Paulo). 2022. https://doi.org/10.1016/J.CLINSP.2022.100073.

Crovetto F, Crispi F, Llurba E, Pascal R, Larroya M, Trilla C, et al. Impact of severe acute respiratory syndrome coronavirus 2 infection on pregnancy outcomes: a population-based study. Clin Infect Dis. 2021;73:1768–75. https://doi.org/10.1093/CID/CIAB104.

Mosnino E, Bernardes LS, Mattern J, HipólitoMicheletti B, de Castro Maldonado AA, Vauloup-Fellous C, et al. Impact of SARS-CoV-2 alpha and gamma variants among symptomatic pregnant women: a two-center retrospective cohort study between France and Brazil. J Clin Med. 2022. https://doi.org/10.3390/JCM11092663.

Perrotta F, Corbi G, Mazzeo G, Boccia M, Aronne L, D'Agnano V, et al. COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. Aging Clin Exp Res. 2020;32:1599. https://doi.org/10.1007/S40520-020-01631-Y.

Kim Y, Yu KM, Koh JY, Kim EH, Kim SM, Kim EJ, et al. Age-dependent pathogenic characteristics of SARS-CoV-2 infection in ferrets. Nat Commun. 2022;13:1–13. https://doi.org/10.1038/s41467-021-27717-3.

Mueller AL, Mcnamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging (Albany NY). 2020;12:9959. https://doi.org/10.18632/AGING.103344.

Belsky JA, Tullius BP, Lamb MG, Sayegh R, Stanek JR, Auletta JJ. COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients. J Infect. 2021;82:329. https://doi.org/10.1016/J.JINF.2021.01.022.

Baek MS, Lee MT, Kim WY, Choi JC, Jung SY. COVID-19-related outcomes in immunocompromised patients: a nationwide study in Korea. PLoS One. 2021. https://doi.org/10.1371/JOURNAL.PONE.0257641.

Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2:1069. https://doi.org/10.1007/S42399-020-00363-4.

WHO updates its treatment guidelines to include molnupiravir n.d. https://www.who.int/news/item/03-03-2022-molnupiravir.

Coronavirus (COVID-19) update: FDA authorizes moderna and Pfizer-BioNTech COVID-19 vaccines for children down to 6 months of age | FDA n.d.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 13915 – 13928
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6521

كوفيد-19: نهج متعدد التخصصات في الرعاية الطارئة، التشخيص المخبري، إدارة الأدوية، الخدمات الاجتماعية، والأمن الصناعي

الملخص

الخلفية: أدى تفشي جائحة كوفيد-19، الناجم عن فيروسSARS-CoV-2 ، إلى تحديات عالمية غير مسبوقة، حيث تم تسجيل أكثر من 601 مليون حالة مؤكدة و6.4 مليون حالة وفاة بحلول سبتمبر 2022. ساهم معدل الطفرات السريع للفيروس، وظهور متحورات مثيرة للقلق، والتفاوتات الاجتماعية والاقتصادية في تعقيد إدارة الجائحة. كما أدت الأوبئة المتزامنة لأمراض معدية أخرى، والعوامل البيئية، وانعدام المساواة في الرعاية الصحية إلى تفاقم الأزمة.

الهدف: يهدف هذا المقال إلى تقديم نظرة شاملة حول الاستراتيجيات متعددة التخصصات التي تم استخدامها لمكافحة كوفيد-19، مع التركيز على الرعاية الطارئة، التطورات في التشخيص، إدارة الأدوية، التطعيم، وأدوار الخدمات الاجتماعية والأمن الصناعي في التخفيف من تأثير الجائحة.

المنهجية: يعتمد البحث على تحليل بيانات من منظمات الصحة العالمية، التجارب السريرية، والدراسات البحثية. يتناول المقال أدوات التشخيص مثلRT-PCR ، وRT-LAMP، وCRISPR-Cas12، والتدخلات العلاجية مثل الأجسام المضادة وحيدة النسيلة والأدوية المضادة للفيروسات، واستراتيجيات التطعيم. كما يتم تحليل أدوار الخدمات الاجتماعية في تسهيل الوصول إلى الرعاية الصحية، وتقديم المساعدات المالية، ودعم الصحة النفسية، إلى جانب تدابير الأمن الصناعي في ضمان سلامة أماكن العمل وإدارة سلاسل التوريد.

النتائج: ساهمت التطورات في التشخيص في تحسين اكتشاف كوفيد-19، حيث لا يزال اختبار RT-PCR هو المعيار الذهبي. أظهرت العلاجات، بما في ذلك الأجسام المضادة وحيدة النسيلة والأدوية المضادة للفيروسات مثل مولنوبيرافير، فعالية في تقليل معدلات الوفيات وحالات دخول المستشفى. حققت حملات التطعيم تغطية عالمية واسعة، حيث أظهرت لقاحات mRNA فعالية عالية ضد المتحورات المختلفة. لعبت الخدمات الاجتماعية والأمن الصناعي أدوارًا حيوية في دعم الفئات الضعيفة، وضمان سلامة بيئات العمل، والحفاظ على استقرار سلاسل التوريد.

الخاتمة: أظهرت جائحة كوفيد-19 أهمية التعاون متعدد التخصصات في التعامل مع الأزمات الصحية العالمية. إن استمرار التطورات في التشخيص، والعلاجات، والتطعيم، إلى جانب تعزيز الخدمات الاجتماعية وتدابير الأمن الصناعي، ضروري للتخفيف من آثار الجائحة والاستعداد لحالات الطوارئ الصحية المستقبلية.

الكلمات المفتاحية: كوفيد-19، SARS-CoV-2، التشخيص، العلاجات، التطعيم، الخدمات الاجتماعية، الأمن الصناعي، النهج متعدد التخصصات.